CSLHAM:CSJ +2.20%73 Gross Margin % is 52.17% as of Dec. 2025, which is 1% below its 10-year median of 52.50. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €171.17 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 738 Biotechnology companies, CSL ranks worse than 58.81% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. CSL's Gross Profit for the
six
months ended in Dec. 2025 was €3,606 Mil. CSL's Revenue for the
six
months ended in Dec. 2025 was €6,911 Mil. Therefore, CSL's Gross Margin % for the quarter that ended in Dec. 2025 was 52.17%.
Warning Sign:
CSL Ltd gross margin has been in long-term decline. The average rate of decline per year is -2.4%.
The historical rank and industry rank for CSL's Gross Margin % or its related term are showing as below:
HAM:CSJ'
s Gross Margin % Range Over the Past 10 Years
Min: 48.65 Med: 52.5 Max: 56.88
Current: 52.18
During the past 13 years, the highestGross Margin % of CSL was 56.88%. The lowest was 48.65%. And the median was 52.50%.
HAM:CSJ's Gross Margin % is ranked worse than 58.81% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs HAM:CSJ: 52.18
CSL had a gross margin of 52.17% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CSL was -2.40% per year.
CSL (HAM:CSJ) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CSL had a gross margin of 52.17% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CSL Gross Margin % Related Terms
CSL Gross Margin % Historical Data
* Premium members only.
The historical data trend for CSL's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:CSJ vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, CSL's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CSL's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CSL (HAM:CSJ) has a Gross Margin % of 52.17% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CSL and its competitors. This is near median its historical median of 52.50. Over the past decade, CSL's Gross Margin % has ranged from 48.65 to 56.88. According to the industry distribution chart, CSL ranks #434 out of 738 companies in the Biotechnology industry, placing it in the top 58.8%.
Is CSL's Gross Margin % too high?
CSL's current Gross Margin % of 52.17% is near median its 10-year median of 52.50. Over the past 10 years, this metric has ranged from a low of 48.65 to a high of 56.88. The Biotechnology industry median Gross Margin % is 60.94. CSL's value of 52.17% is 14.4% below this industry median. Based on the distribution chart, CSL ranks #434 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #434 out of 738 companies for Gross Margin %. This places CSL in the lower half of its industry. The industry median Gross Margin % is 60.94. CSL's value of 52.17% is 14.4% below this benchmark. Historically, CSL's own Gross Margin % has ranged from 48.65 to 56.88 over the past decade. While the company's 10-year median is 52.50 vs. the industry median of 60.94, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Gross Margin % of 52.17% is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CSL and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Gross Margin % is 52.17%, which is near median its own 10-year median of 52.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €171.17, compared to a current price of €69.73 — trading 59.3% below its estimated fair value. The current Gross Margin % is 52.17%, which is near median its 10-year median of 52.50 and 14.4% below the Biotechnology industry median of 60.94. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CSL (HAM:CSJ), the current Gross Margin % is 52.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €69.73 is trading 59.3% below its estimated GF Value™ of €171.17.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
Gross Margin %: 52.17% (near median its 10-year median of 52.50)
GF Value™: €171.17 vs. price of €69.73 (59.3% below fair value)
Industry Position: 14.4% below the Biotechnology median (#434 of 738)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
